Deemea

• You require a diagnostic-cleared viewer/workflow (CE/FDA) for clinical use: Deemea states the platform is for research use only and not for diagnostic procedures. (https://deemea.com/legalinfo)
• You need extensive peer review coverage on Gartner/G2/TrustRadius before procurement: Deemea has limited presence on these platforms based on accessible searches.
• You require transparent list pricing for rapid procurement comparisons: Deemea does not publish pricing, unlike some alternatives. (https://deemea.com/) (https://www.medicai.io/pricing)
• You primarily need DICOM storage and indexing APIs to build a custom platform: infrastructure-first services such as AWS HealthImaging may better match that need. (https://aws.amazon.com/healthimaging/pricing/)

Vendor and investor materials reference interoperability and APIs, but public technical documentation or developer guides were not located in the accessed sources. Buyers should request API documentation, integration guides, and example implementations during technical due diligence. (https://www.karista.vc/stories/deemea-announces-a-eu4-million-funding-round-to-step-up-the-european-deployment-of-its-ai-platform-dedicated-to-clinical-research)

• Framing around study-oriented imaging workflows that cover collection, QC, annotation, and multicenter visualization.
• Described on-premises deployment option at investigator centers that may support specific data residency or sovereignty requirements. (https://deemea.com/legalinfo)
• Investor and vendor statements reference a set of machine-learning models and automated QC algorithms intended to support quality control; these are vendor-provided claims and should be validated in technical evaluation. (https://www.karista.vc/stories/deemea-announces-a-eu4-million-funding-round-to-step-up-the-european-deployment-of-its-ai-platform-dedicated-to-clinical-research)

• Transparent pricing and trial options are offered by vendors such as Medicai, which can simplify initial evaluations. (https://www.medicai.io/pricing)
• Cloud-native, metered infrastructure options such as AWS HealthImaging provide documented usage billing and scalability for organizations building custom platforms. (https://aws.amazon.com/healthimaging/pricing/)
• Some enterprise vendors and larger CROs publish more extensive security and compliance documentation publicly; Deemea’s public security posture is less documented in accessible sources.

Deemea appears to be a small, specialized B2B vendor (public profiles indicate a small team) and does not have visible listings or reviews on mainstream software review platforms based on the searches performed:

• Gartner Peer Insights: no Deemea-specific listing surfaced in accessible results (general Peer Insights portal pages found).
• G2: no Deemea listing surfaced in search results.
• TrustRadius, Capterra / Software Advice / GetApp: no Deemea listings surfaced in accessible search results.

As a result, there are no independently verifiable star-rated reviews or user quotes from mainstream review platforms included here.

Public vendor-controlled channels (e.g., vendor LinkedIn posts) include performance metrics presented as exact figures, such as:

• claims of a very large reduction in data collection time
• claims of significant shortening of timelines
• claims of a meaningful increase in productivity

These statements are presented by the vendor and are not accompanied by methodology, sample size, or named customer references in the source material; they should be treated as unverified marketing metrics until validated by pilots or third-party reporting. (Public vendor LinkedIn post)

Deemea is a clinical research imaging data platform intended to support imaging workflows for clinical studies. Core capabilities described by the vendor include connecting to hospital systems (notably PACS), retrieving imaging exams, performing automated quality control checks, enabling annotation and review, and supporting visualization across multiple study sites. The product is presented as targeted to research workflows rather than clinical diagnosis.

Vendor materials reference direct PACS connectivity (marketed as “Collaborative Research PACS”), an interactive viewer with automated pre-annotation features, multicenter visualization, and claims about reduced time from acquisition to visualization. (Vendor website: product overview and feature pages)

Based on vendor and investor descriptions, Deemea primarily targets:

• Biopharmaceutical sponsors and medical device companies conducting imaging-heavy trials
• Investigator sites and hospitals participating in multicenter studies
• Clinical research operations teams that manage imaging collection, QC, annotation, and standardized outputs across sites

The vendor describes deployments across healthcare centers in France, Belgium, Germany, Italy, and Spain, with stated plans for broader expansion. (Vendor website: deployment and case study pages)